Hyperliquid Strategies Inc. (PURR)

NASDAQ: PURR · Real-Time Price · USD
6.99
-0.15 (-2.10%)
At close: May 15, 2026, 4:00 PM EDT
7.01
+0.02 (0.29%)
After-hours: May 15, 2026, 7:58 PM EDT
Market Cap866.53M
Revenue (ttm)n/a
Net Incomen/a
EPSn/a
Shares Out 123.97M
PE Ration/a
Forward PE9.40
Dividendn/a
Ex-Dividend Daten/a
Volume10,876,316
Open6.78
Previous Close7.14
Day's Range6.54 - 7.22
52-Week Range3.01 - 7.37
Betan/a
AnalystsStrong Buy
Price Target8.11 (+16.02%)
Earnings DateMay 7, 2026

About PURR

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Sector Financials
Founded 2025
Country United States
Stock Exchange NASDAQ
Ticker Symbol PURR
Full Company Profile

Analyst Summary

According to 4 analysts, the average rating for PURR stock is "Strong Buy." The 12-month stock price target is $8.11, which is an increase of 16.02% from the latest price.

Price Target
$8.11
(16.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Hyperliquid Strategies (PURR) to $8 from $6 and keeps an Overweight rating on the shares. Hyperliquid Strategies is one of the most…

5 days ago - TheFly

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

Q3 saw strong net income driven by HYPE token appreciation and effective treasury management, with expanded ecosystem participation through a new validator and rapid adoption of real world asset and outcome markets. Cash reserves remain robust, and capital allocation is flexible.

9 days ago - Transcripts

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

Hyperliquid Strategies (PURR) and Unit Labs announced the launch of a new validator operating under the name Hyperliquid Strategies x Unit, expected to go live on or around May 11,…

9 days ago - TheFly

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

NEW YORK, May 7, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today report...

9 days ago - PRNewsWire

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

NEW YORK, May 7, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, and Unit Labs ("UNIT"), the p...

9 days ago - PRNewsWire

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

NEW YORK, April 28, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today ann...

18 days ago - PRNewsWire

Hyperliquid Strategies initiated with a Buy at Maxim

Maxim analyst Matthew Galinko initiated coverage of Hyperliquid Strategies (PURR) with a Buy rating and $10 price target The company’s digital asset treasury is built around the Hyperliquid ecosystem,...

22 days ago - TheFly

Hyperliquid Strategies initiated with a Buy at Maxim

Maxim initiated coverage of Hyperliquid Strategies (PURR) with a Buy rating and $10 price target

22 days ago - TheFly

Hyperliquid Strategies begins trading options in Nasdaq Options Market

Hyperliquid Strategies (PURR) announced that options trading on its common stock has commenced on the Nasdaq Options Market. This development enhances liquidity, price discovery, and investor access t...

7 weeks ago - TheFly

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

NEW YORK, March 24, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today ann...

7 weeks ago - PRNewsWire

One new option listing and sixteen option delistings on March 24th

New option listings for March 24th include Hyperliquid Strategies Inc Common Stock (PURR). Option delistings effective March 24th include Alexander & Baldwin Inc (Hawaii) (ALEX), Tradr 2X Long AUR Dai...

7 weeks ago - TheFly

Hyperliquid Strategies price target raised to $6 from $5 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Hyperliquid Strategies (PURR) to $6 from $5 and keeps an Overweight rating on the shares. Hyperliquid Strategies reported its first public-quarter r...

3 months ago - TheFly

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

NAV per share accretion remains the top priority, with $140M deployed in HYPE tokens and share buybacks. Despite a $318M net loss driven by HYPE price declines, strong cash reserves and platform growth position the company for continued execution and transparency.

3 months ago - Transcripts

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today repo...

3 months ago - PRNewsWire

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hyperliquid Strategies Inc (NASDAQ: PURR) ("HSI" or the "Company"), the premier digital asset treasury platform focused on the Hyperliquid ecosystem, today annou...

3 months ago - PRNewsWire

Hyperliquid Strategies initiated with a Buy at Chardan

Chardan initiated coverage of Hyperliquid Strategies (PURR) with a Buy rating and $8.15 price target

5 months ago - TheFly

Cantor starts Hyperliquid treasury company Hyperliquid Strategies at Overweight

As previously reported, Cantor Fitzgerald analyst Brett Knoblauch initiated coverage of Hyperliquid (HYPE-USD) Strategies (PURR) with an Overweight rating and $5 price target Hyperliquid Strategies is...

5 months ago - TheFly

Hyperliquid Strategies initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Hyperliquid Strategies (PURR) with an Overweight rating and $5 price target

5 months ago - TheFly

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Hyperliquid Strategies Inc (NASDAQ: PURR) (“HSI” or the “Company”) announced today that its Board of Directors has authorized a stock repurchase program of ...

5 months ago - GlobeNewsWire

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Hyperliquid Strategies Inc. chairman Bob Diamond and Hyperliquid Stategies Inc. CEO David Schamis comment on the future of Hyperliquid Strategies Inc. on ‘The Claman Countdown.'

5 months ago - Fox Business

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wedn...

5 months ago - GlobeNewsWire

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockh...

6 months ago - GlobeNewsWire

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patie...

7 months ago - GlobeNewsWire

Sonnet to Present at the MedInvest Biotech & Pharma Conference

PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete...

8 months ago - GlobeNewsWire

Sonnet Releases Virtual Investor "What This Means" Segment

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)

9 months ago - GlobeNewsWire